Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Trial Profile

Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs MBG 453 (Primary) ; PDR 001 (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 17 May 2017 Planned End Date changed from 20 Apr 2019 to 5 Jun 2019.
    • 17 May 2017 Planned primary completion date changed from 20 Apr 2019 to 5 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top